Skip to content

Clinical trials

Phase 1/2 Recurrence trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Recurrence Phase: Phase 1/2 Country / region: United States Clear all

219 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20005
20035
20043
20054
20065
20074
20087
20093
20107
201111
201212
20135
201414
20156
201613
201714
20189
201914
202010
202111
202212
202311
202413
202511
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed79
Terminated57
Recruiting42
Active, not recruiting21
Unknown status7
Withdrawn6
Not yet recruiting5
Suspended2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center11
Memorial Sloan Kettering Cancer Center8
Fred Hutchinson Cancer Center5
National Cancer Institute (NCI)5
Therapeutic Advances in Childhood Leukemia Consortium5
Celgene4
Dana-Farber Cancer Institute4
Regeneron Pharmaceuticals4
Altor BioScience3
AstraZeneca3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Recurrence219
Multiple Myeloma40
Lymphoma32
Neoplasms31
Leukemia28
Leukemia, Myeloid, Acute28
Leukemia, Lymphocytic, Chronic, B-Cell25
Lymphoma, Non-Hodgkin25
Lymphoma, Large B-Cell, Diffuse20
Neoplasm Metastasis20

Trials

Showing 1 to 25 of 219. Each trial links to its page on Pharma Observatory.

119 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.